6 completed, 5 unknown, 2 terminated, 1 active not recruiting. 7 Phase 2, 3 Not applicable, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Unknown 2, Terminated 1 |
| Not applicable | 3 | Unknown 2, Completed 1 |
| Phase 1 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Terminated 1, Unknown 1 |
Follow Becaplermin: new trials by email Literature Review of Becaplermin trials Research Report on Becaplermin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction RhPDGF-BB, Saline - Wound Healing, Surgical Wound | Phase 2 | Completed | Vanderbilt University Medical Center | 36 | 2025-04-01 | 2026-08-12 |
| Evaluating an rhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing RhPDGF-BB - Anal Fistula, Complex Perianal Fistula | Phase 2 | Completed | Alexander Hawkins | 13 | 2024-11-25 | 2026-08-03 |
| Periodontal Regeneration With Recombinant Human Platelet Derived Growth Factor (rH-PDGF-BB) and Allograft Allograft and rHPDGF-BB, Allograft and Saline solution - Periodontal Diseases | Phase 2 | Unknown | Universidad Autonoma de Nuevo Leon | 30 | 2024-01-10 | 2024-05-01 |
| Release Kinetics in PRF Versus GEM21S With and Without Bone Substitutes: An In Vitro Analysis Amount of PDGF-BB in PRF preparation vs. GEM21, Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation, Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes - Bone Loss | Active not recruiting | University of Alabama at Birmingham | 5 | 2021-08-31 | 2025-12-02 | |
| Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing Becaplermin, Promagran Dressing, Placebo Dressing - Venous Ulcer, Foot Ulcer, Diabetic | Phase 3 | Unknown | McMaster University | 80 | 2018-08-01 | 2018-04-09 |
| Evaluation of ABSOLVE in Diabetic Foot Ulcers RhPDGF-BB, Placebo - Diabetic Foot Ulcers | Phase 2 | Unknown | Lynch Biologics LLC | 40 | 2017-01-30 | 2017-01-31 |
| Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PD i.c.v. infusion of sNN0031 by an Implanted infusion system, i.c.v. infusion of aCSF by an Implanted infusion system - Parkinson's Disease | Phase 1 / Phase 2 | Terminated | Newron Sweden AB | 1 | 2015-01-01 | 2016-01-27 |
| Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers AMD3100 injection + rhPDGF-BB topical - Diabetic Ulcer | Phase 1 | Withdrawn | NYU Langone Health | 2014-04-01 | 2016-03-04 | |
| Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis rhPDGF-BB Injection, Placebo - Lateral Epicondylitis | Phase 2 | Completed | BioMimetic Therapeutics | 100 | 2012-12-12 | 2019-07-02 |
| Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer Biochaperone PDGF-BB Low dose, Biochaperone PDGF-BB High dose, Regranex - Diabetic Foot Ulcers | Phase 1 / Phase 2 | Completed | Virchow Group | 192 | 2010-06-01 | 2014-12-15 |
| Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers Regranex®, Hydrogel - Diabetic Foot Ulcers | Not applicable | Unknown | Southern California Institute for Research and Education | 60 | 2007-04-01 | 2010-06-04 |
| TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers TheraGauze, Regranex - Diabetic Foot Ulcer | Not applicable | Unknown | Solsys Medical LLC | 30 | 2006-09-01 | 2008-05-07 |
| The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin]) REGRANEX (becaplermin), REGRANEX (becaplermin) comparators - Diabetes Mellitus | Completed | Ethicon, Inc. | 4431 | 2003-01-01 | 2016-07-19 | |
| A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX Becaplermin - Foot Ulcer, Diabetic Foot | Phase 3 | Terminated | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 84 | 2000-12-01 | 2011-06-08 |
| Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain B-TCP + 0.3 mg/ml rhPDGF-BB in buffer, B-TCP + 1.0 mg/ml rhPDGF-BB in buffer, B-TCP +buffer - Periodontitis | Not applicable | Completed | University of Michigan | 180 | 2000-01-01 | 2016-01-08 |
Diabetic Foot (6) · Diabetes Mellitus (4) · Diabetic Neuropathies (2) · Bone Diseases, Metabolic (1) · Foot Ulcer (1) · Neoplasms (1) · Osteogenesis Imperfecta, Type IV (1) · Parkinson Disease (1) · Periodontal Diseases (1) · Periodontitis (1) · Peripheral Vascular Diseases (1) · Rectal Fistula (1) · Skin Ulcer (1) · Surgical Wound (1) · Tennis Elbow (1)
Alexander Hawkins (1) · BioMimetic Therapeutics (1) · Ethicon, Inc. (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Lynch Biologics LLC (1) · McMaster University (1) · NYU Langone Health (1) · Newron Sweden AB (1) · Solsys Medical LLC (1) · Southern California Institute for Research and Education (1) · Universidad Autonoma de Nuevo Leon (1) · University of Alabama at Birmingham (1) · University of Michigan (1) · Vanderbilt University Medical Center (1) · Virchow Group (1)
United States (8) · Canada (1) · Germany (1) · Guatemala (1) · India (1) · Mexico (1) · Sweden (1) · United Kingdom (1)
Adam Landsman, DPM, PhD (1) · Aksone Nouvong, D.P.M. (1) · Alexander T Hawkins (1) · Anne Laumann, MBChB, MRCP (1) · Edward Akelman, MD (1) · Ian Gordon, M.D., Ph.D. (1) · Luis Gonzalez, MD (1)
PMID 16332231, PMID 22612364, PMID 40952157, PMID 29703712, PMID 42145621, PMID 42396268